A Palmitoylation-Associated lncRNA Signature as a Prognostic Biomarker and Its Correlation With the Immune Microenvironment in Lung Adenocarcinoma
Frontiers in Bioscience-Landmark · 22.05.2026 · 31 (5)
DOI: 10.31083/fbl48267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 22.05.2026. Verfasst von Wenxin Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, 421001 Hengyang, Hunan, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Lung Neoplasms, Biomarkers, Tumor, Lipoylation. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Fund Project of the Hunan Provincial Health Commission, Hunan Provincial Graduate Research and Innovation General Project.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is recognized as the predominant subtype of non-small cell lung cancer (NSCLC), characterized by its aggressive behavior and notable capacity for metastasis. Recent studies have uncovered the significance of palmitoylation, a vital post-translational modification, in regulating biological functions such as cellular signaling and protein localization, suggesting its potential role in cancer biology. However, the implications of palmitoylation-associated long non-coding RNAs (lncRNAs) in LUAD pathology remain insufficiently characterized.
Methods
Utilizing publicly available datasets, we conducted an extensive bioinformatics analysis to evaluate the expression and prognostic significance of palmitoylation-associated lncRNAs in LUAD. Our analysis identified 13 lncRNAs as potential prognostic biomarkers. Specifically, we sought to develop a prognostic model based on these lncRNAs to improve our understanding of their contribution to LUAD prognosis. The robustness of the prognostic model was subsequently verified through survival analysis and receiver operating characteristic (ROC) curve assessments.
Results
This study established a prognostic risk model based on 13 palmitoylation-related lncRNAs, demonstrating excellent predictive performance, with area under the curve (AUC) values of 0.743, 0.724, and 0.748 for 1-year, 3-year, and 5-year overall survival, respectively. Multivariate Cox regression analysis indicated that the model’s risk score serves as an independent prognostic predictor, surpassing traditional clinicopathological features. Differential expression analysis and quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation revealed significant downregulation of AL157895.1 in LUAD tissues and cell lines, whereas AL355472.3, SALRNA1, AL590666.4, AC026355.2, and LINC00862 were significantly upregulated. Importantly, low expression of AL157895.1 was strongly associated with poor patient prognosis.
Conclusions
The findings underscore the potential of palmitoylation-associated lncRNAs as independent prognostic markers for patients with LUAD, paving the way for more personalized treatment approaches. Future studies should further explore their biological mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, 421001 Hengyang, Hunan, China.
- Department of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, The First Affiliated Hospital of Jishou University, 416000 Jishou, Hunan, China.
- Department of Thoracic Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, 421001 Hengyang, Hunan, China.
Förderung
- Scientific Research Fund Project of the Hunan Provincial Health Commission
- Hunan Provincial Graduate Research and Innovation General Project
Zitieren
APA
Ding, W., Wu, S., Zeng, L., Fan, Z., Luo, Y., Yi, X., Wang, P., Mo, L., & Li, Y. (2026). A Palmitoylation-Associated lncRNA Signature as a Prognostic Biomarker and Its Correlation With the Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark, 31(5). https://doi.org/10.31083/fbl48267
Vancouver
Ding W, Wu S, Zeng L, Fan Z, Luo Y, Yi X, et al. A Palmitoylation-Associated lncRNA Signature as a Prognostic Biomarker and Its Correlation With the Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark. 2026;31(5). doi:10.31083/fbl48267
BibTeX
@article{Ding2026,
author = {Ding, Wenxin and Wu, Sixuan and Zeng, Lijun and Fan, Zhongxiang and Luo, Yongmei and Yi, Xinyu and Wang, Pan and Mo, Liang and Li, Yuehua},
title = {A Palmitoylation-Associated lncRNA Signature as a Prognostic Biomarker and Its Correlation With the Immune Microenvironment in Lung Adenocarcinoma},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {5},
doi = {10.31083/fbl48267}
}
EUVIMED